Lobelia Pharma SRL
Lobelia Pharma reported total assets of €3.55m at the end of the 2025 financial year (annual accounts filed with the NBB on 16 Jul 2026).
The score of Lobelia Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +58 % Total assets +73 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Lobelia Pharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 16 Jul 2026
- Year ended 31 Dec 2024filed on 13 Aug 2025
- Year ended 31 Dec 2023filed on 08 Aug 2024
- Year ended 31 Dec 2022filed on 31 Mar 2023
- Year ended 31 Dec 2021filed on 11 Aug 2022
Lobelia Pharma's financial analysis
- Solvency42.7%sector median: 58.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Lobelia Pharma
Lobelia Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0471.133.849
- VAT number
- BE0471133849
- Peppol
- Registered · 0208:0471133849 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 23 Feb 2000
- Registered office
- 8200 Bruges
- Latest accounts
- 2025 · filed on 16 Jul 2026
- Activity
- Business and other management consultancy activities (NACE 70200)
Lobelia Pharma (SRL) has been based in Bruges since 2000, active in: business and other management consultancy activities. For 2025, it reports a net profit of 274,161 € and equity of €1.51m; its revenue is not published. Its solvency stands at 42.7%, below the median of its sector (58.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Lobelia Pharma
Companies in the same business, of comparable size and area, outside its group.
- Vasimev Business and other management consultancy activities Sint-Martens-Latem · balance sheet €3.54m
- Legadema International Business and other management consultancy activities Putte · balance sheet €3.54m
- SQG Business and other management consultancy activities Waregem · balance sheet €3.53m
- PN Invest Business and other management consultancy activities Hasselt · balance sheet €3.53m
- Aktea Business and other management consultancy activities Neupré · balance sheet €3.56m
- Cafa Invest Business and other management consultancy activities Berchem-Sainte-Agathe · balance sheet €3.57m
- I.B.E. Invest Business and other management consultancy activities Mons · balance sheet €3.52m
- K.M.O. Advies Business and other management consultancy activities Deinze · balance sheet €3.52m
Frequently asked questions about Lobelia Pharma
What is the revenue of Lobelia Pharma?
Lobelia Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Lobelia Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0471133849 for Lobelia Pharma, if the company is VAT-registered. Its company number (CBE) is 0471.133.849.
Where is the registered office of Lobelia Pharma?
According to the CBE register, the registered office of Lobelia Pharma is in 8200 Bruges.
What is the equity of Lobelia Pharma?
At the close of the 2025 financial year, the equity of Lobelia Pharma amounts to 1,514,663 €, a solvency of 42.7% of total assets.
Who manages Lobelia Pharma?
The register lists 1 active mandates at Lobelia Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Lobelia Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →